Sanatan Saraf

6.0k total citations · 5 hit papers
43 papers, 4.2k citations indexed

About

Sanatan Saraf is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Sanatan Saraf has authored 43 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Sanatan Saraf's work include Cancer Immunotherapy and Biomarkers (34 papers), Lung Cancer Treatments and Mutations (13 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Sanatan Saraf is often cited by papers focused on Cancer Immunotherapy and Biomarkers (34 papers), Lung Cancer Treatments and Mutations (13 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Sanatan Saraf collaborates with scholars based in United States, France and Taiwan. Sanatan Saraf's co-authors include Sarina A. Piha‐Paul, Patrick A. Ott, Emilie M.J. van Brummelen, Anne Morosky, Bilal Piperdi, Élena Elez, Christophe Le Tourneau, Hope S. Rugo, Juanita Lopez and Andréa Varga and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Sanatan Saraf

42 papers receiving 4.2k citations

Hit Papers

Safety and Efficacy of Pembrolizumab in Advanced, Program... 2017 2026 2020 2023 2017 2017 2017 2017 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
    2017 386 citations Jean‐Sébastien Frenel, Christophe Le Tourneau et al. Journal of Clinical Oncology profile →
  2. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
    2017 377 citations Patrick A. Ott, Yung‐Jue Bang et al. Journal of Clinical Oncology profile →
  3. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
    2017 363 citations Patrick A. Ott, Élena Elez et al. Journal of Clinical Oncology profile →
  4. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
    2017 325 citations Evan Alley, Juanita Lopez et al. The Lancet Oncology profile →
  5. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
    2017 300 citations Samuel Ejadi, Caroline Even et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sanatan Saraf United States 25 3.3k 1.5k 977 800 451 43 4.2k
Snjezana Doğan United States 31 2.0k 0.6× 1.4k 0.9× 1.3k 1.3× 327 0.4× 1.2k 2.6× 89 4.6k
Ellie Im United States 13 4.9k 1.5× 3.1k 2.0× 370 0.4× 1.1k 1.4× 510 1.1× 31 5.5k
Aleš Ryška Czechia 29 1.8k 0.5× 793 0.5× 1.4k 1.4× 389 0.5× 679 1.5× 189 3.6k
Z. Alexander Cao United States 18 3.7k 1.1× 1.1k 0.7× 763 0.8× 860 1.1× 654 1.5× 40 4.4k
Kosei Hasegawa Japan 26 1.4k 0.4× 508 0.3× 486 0.5× 482 0.6× 678 1.5× 179 3.0k
Annamaria H. Zimmermann United States 18 2.0k 0.6× 1.6k 1.0× 1.6k 1.6× 135 0.2× 574 1.3× 60 3.6k
Sreenivasa Nattam United States 20 1.9k 0.6× 1.0k 0.7× 288 0.3× 182 0.2× 760 1.7× 42 2.6k
Willeke Ros Netherlands 14 1.6k 0.5× 436 0.3× 666 0.7× 593 0.7× 293 0.6× 22 2.2k
Vera Gorbounova Russia 13 2.2k 0.7× 1.8k 1.2× 280 0.3× 151 0.2× 617 1.4× 23 3.2k
Vincent van der Noort Netherlands 23 1.3k 0.4× 1.4k 1.0× 286 0.3× 294 0.4× 266 0.6× 133 2.5k

Countries citing papers authored by Sanatan Saraf

Since Specialization
Citations

This map shows the geographic impact of Sanatan Saraf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanatan Saraf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanatan Saraf more than expected).

Fields of papers citing papers by Sanatan Saraf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sanatan Saraf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanatan Saraf. The network helps show where Sanatan Saraf may publish in the future.

Co-authorship network of co-authors of Sanatan Saraf

This figure shows the co-authorship network connecting the top 25 collaborators of Sanatan Saraf. A scholar is included among the top collaborators of Sanatan Saraf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sanatan Saraf. Sanatan Saraf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Awad, Mark M., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2021). OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology. 16(1). S8–S8. 1 indexed citations
4.
Mehnert, Janice M., Andréa Varga, Marcia S. Brose, et al.. (2019). Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer. BMC Cancer. 19(1). 196–196. 148 indexed citations
5.
Ott, Patrick A., Yung‐Jue Bang, Dominique Berton-Rigaud, et al.. (2018). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Obstetrical & Gynecological Survey. 73(1). 26–27. 25 indexed citations
6.
Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2018). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(1). 124–129. 169 indexed citations
7.
Yang, James Chih‐Hsin, Shirish M. Gadgeel, Chien-Liang Wu, et al.. (2018). Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. Journal of Thoracic Oncology. 14(3). 553–559. 130 indexed citations
8.
Gadgeel, Shirish M., James Stevenson, Corey J. Langer, et al.. (2018). Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 125. 273–281. 68 indexed citations
9.
Gubens, Matthew A., Lecia V. Sequist, James Stevenson, et al.. (2018). Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer. 130. 59–66. 74 indexed citations
10.
Ott, Patrick A., Yung‐Jue Bang, Dominique Berton-Rigaud, et al.. (2017). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Journal of Clinical Oncology. 35(22). 2535–2541. 377 indexed citations breakdown →
11.
Frenel, Jean‐Sébastien, Christophe Le Tourneau, Bert H. O’Neil, et al.. (2017). Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. Journal of Clinical Oncology. 35(36). 4035–4041. 386 indexed citations breakdown →
12.
Alley, Evan, Juanita Lopez, Armando Santoro, et al.. (2017). OA13.03 Long-Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE-028. Journal of Thoracic Oncology. 12(1). S294–S294. 10 indexed citations
13.
Plimack, Elizabeth R., Joaquim Bellmunt, Shilpa Gupta, et al.. (2017). Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. The Lancet Oncology. 18(2). 212–220. 259 indexed citations
14.
Ott, Patrick A., Sarina A. Piha‐Paul, Pamela N. Münster, et al.. (2017). Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Annals of Oncology. 28(5). 1036–1041. 164 indexed citations
15.
Alley, Evan, Juanita Lopez, Armando Santoro, et al.. (2017). Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. The Lancet Oncology. 18(5). 623–630. 325 indexed citations breakdown →
16.
Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2017). Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC. Annals of Oncology. 28. v636–v637. 19 indexed citations
17.
Lee, Victor, Roger K.C. Ngan, Quan Sing Ng, et al.. (2016). 394TiP KEYNOTE-122: Phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma. Annals of Oncology. 27. ix122–ix122. 3 indexed citations
18.
Hansen, Aaron R., Christophe Massard, Naomi B. Haas, et al.. (2016). Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study. Annals of Oncology. 27. vi247–vi247. 36 indexed citations
19.
Hsu, Chih‐Hung, Seung‐Hoon Lee, Samuel Ejadi, et al.. (2015). 315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study. Annals of Oncology. 26. ix93–ix93. 13 indexed citations
20.
Saraf, Sanatan, Thomas Mathew, & Anindya Roy. (2014). Statistical Validation of Surrogate Endpoints: Another Look at the Prentice Criterion and Other Criteria. Journal of Biopharmaceutical Statistics. 25(6). 1234–1246. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Snjezana Doğan Breakdown of academic impact, for papers by Ellie Im Breakdown of academic impact, for papers by Aleš Ryška Breakdown of academic impact, for papers by Z. Alexander Cao Breakdown of academic impact, for papers by Kosei Hasegawa Breakdown of academic impact, for papers by Annamaria H. Zimmermann Breakdown of academic impact, for papers by Sreenivasa Nattam Breakdown of academic impact, for papers by Willeke Ros Breakdown of academic impact, for papers by Vera Gorbounova Breakdown of academic impact, for papers by Vincent van der Noort
Rankless by CCL
2026